Standardization and validation issues of the ELISPOT assay.

During the last 20 yr, the enzyme-linked immunospot (ELISPOT) assay has emerged as one of the most important and widely used assays to monitor immune responses in humans and a variety of other species. With the ELISPOT assay, immune cell frequencies can be measured at the single cell level without elaborate expansion or manipulation of cell populations. Its usefulness has led to its application in vaccine design and development and, most importantly, in monitoring vaccination efforts. The impact of results measured with this assay can be profound. In addition to ease of performance, repeatability and reliability are major features expected of an ELISPOT assay. The focus today is on standardization of the technique, validation strategies to comply with these required features, and accommodation of the growing demand of Good Laboratory Practice (GLP) compliance. This chapter will give the experienced scientists as well as newcomers to the field an overview over the major standardization issues for each step of the protocol. Guidelines are given on how to validate the ELISPOT performance.

[1]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[2]  J. Fleiss.  Statistical methods for rates and proportions , 1974 .

[3]  P. Kaleebu,et al.  Cross‐clade recognition of p55 by cytotoxic T lymphocytes in HIV‐1 infection , 1998, AIDS.

[4]  A. McMichael,et al.  Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines. , 2002, AIDS research and human retroviruses.

[5]  Paul V. Lehmann,et al.  Single-Cytokine-Producing CD4 Memory Cells Predominate in Type 1 and Type 2 Immunity1 , 2000, The Journal of Immunology.

[6]  R. Shaw,et al.  Persistence of intestinal antibody response to heterologous rotavirus infection in a murine model beyond 1 year , 1993, Journal of clinical microbiology.

[7]  S. S. Young,et al.  Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment , 1993 .

[8]  Bernhard O. Boehm,et al.  A T Cell Clone’s Avidity Is a Function of Its Activation State1 , 2001, The Journal of Immunology.

[9]  B. Ferruà,et al.  Reverse ELISPOT assay for clonal analysis of cytokine production. II. Enumeration of interleukin-1-secreting cells by amplified (avidin-biotin anti-peroxidase) assay. , 1992, Journal of immunological methods.

[10]  Charles W. Dunnett,et al.  New tables for multiple comparisons with a control. , 1964 .

[11]  P. Holt,et al.  A solid-phase immunoenzymatic technique for the enumeration of specific antibody-secreting cells. , 1983, Journal of immunological methods.

[12]  R. Wilkinson,et al.  High frequencies of circulating IFN‐γ‐secreting CD8 cytotoxic T cells specific for a novel MHC class I‐restricted Mycobacterium tuberculosis epitope in M. tuberculosis‐infected subjects without disease , 2000 .

[13]  M. Davis,et al.  Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. , 1999, Journal of immunology.

[14]  Gregory R. Grant,et al.  Statistical Methods in Bioinformatics , 2001 .

[15]  A. Eggermont,et al.  Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. , 2000, Journal of immunological methods.

[16]  Russell D. Wolfinger,et al.  Multiple Comparisons and Multiple Tests Using the SAS System , 1999 .

[17]  O Ouchterlony,et al.  A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. , 1983, Journal of immunological methods.

[18]  P. S. Richards,et al.  Cytokine Release by Single, Immunophenotyped Human Cells: Use of the Reverse Hemolytic Plaque Assay , 1991, Immunological reviews.

[19]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Xu Liu,et al.  Development and Validation of a Gamma Interferon ELISPOT Assay for Quantitation of Cellular Immune Responses to Varicella-Zoster Virus , 2001, Clinical Diagnostic Laboratory Immunology.

[21]  C. Mogensen.  The glomerular permeability determined by dextran clearance using Sephadex gel filtration. , 1968, Scandinavian journal of clinical and laboratory investigation.

[22]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[23]  Sylvia Janetzki,et al.  A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. , 2002, Journal of immunological methods.

[24]  M. V. von Herrath,et al.  CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge , 1996, Journal of virology.

[25]  B. Boehm,et al.  CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. , 2003, Journal of immunological methods.

[26]  S Janetzki,et al.  Evaluation of Elispot assays: influence of method and operator on variability of results. , 2004, Journal of immunological methods.

[27]  Y. Cui,et al.  Computer-assisted, quantitative cytokine enzyme-linked immunospot analysis of human immune effector cell function. , 1997, BioTechniques.

[28]  M. Mulligan,et al.  Magnitude of Functional CD8+ T-Cell Responses to the Gag Protein of Human Immunodeficiency Virus Type 1 Correlates Inversely with Viral Load in Plasma , 2002, Journal of Virology.

[29]  T. Whiteside,et al.  Evaluation of the Modified ELISPOT Assay for Gamma Interferon Production in Cancer Patients Receiving Antitumor Vaccines , 2000, Clinical Diagnostic Laboratory Immunology.

[30]  A. Bøyum,et al.  Isolation of mononuclear cells and granulocytes from human blood. , 1968 .

[31]  D. Birx,et al.  Comprehensive Screening for Human Immunodeficiency Virus Type 1 Subtype-Specific CD8 Cytotoxic T Lymphocytes and Definition of Degenerate Epitopes Restricted by HLA-A0207 and -CW0304 Alleles , 2002, Journal of Virology.

[32]  E. Wherry,et al.  Viral Persistence Alters CD8 T-Cell Immunodominance and Tissue Distribution and Results in Distinct Stages of Functional Impairment , 2003, Journal of Virology.

[33]  Rebecca A. Betensky,et al.  Shipment Impairs Lymphocyte Proliferative Responses to Microbial Antigens , 2000, Clinical Diagnostic Laboratory Immunology.

[34]  Charles M. Rice,et al.  HCV Persistence and Immune Evasion in the Absence of Memory T Cell Help , 2003, Science.

[35]  R. Ahmed,et al.  CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection , 1994, Journal of virology.

[36]  O Ouchterlony,et al.  Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. , 1988, Journal of immunological methods.

[37]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[38]  N. Câmara,et al.  Human CD4+CD25+ regulatory cells have marked and sustained effects on CD8+ T cell activation , 2003, European journal of immunology.

[39]  N. Leister,et al.  The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens. , 1997, Journal of immunological methods.

[40]  R. Steinman,et al.  A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. , 1999, AIDS.

[41]  Sylvia Janetzki,et al.  Evaluation of CD8+ T‐cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide , 2000, International journal of cancer.

[42]  S. Groshen,et al.  Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  J. Schneider-Mergener,et al.  Target Structures of the CD8+-T-Cell Response to Human Cytomegalovirus: the 72-Kilodalton Major Immediate-Early Protein Revisited , 1999, Journal of Virology.

[44]  E. Tartour,et al.  A Fluorospot assay to detect single T lymphocytes simultaneously producing multiple cytokines. , 2003, Journal of immunological methods.

[45]  Jonathan J. Lewis,et al.  Immunization of cancer patients with autologous cancer‐derived heat shock protein gp96 preparations: A pilot study , 2000, International journal of cancer.

[46]  S. Rosenberg,et al.  Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. , 1998, The cancer journal from Scientific American.

[47]  A. Tamhane,et al.  Multiple Comparison Procedures , 1989 .

[48]  M. Altfeld,et al.  Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. , 2003, Journal of immunological methods.